We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -74.00 | -0.60% | 12,172.00 | 12,166.00 | 12,170.00 | 12,306.00 | 12,132.00 | 12,240.00 | 1,412,854 | 16:35:18 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.68 | 188.63B |
From May 2019 to May 2024
AstraZeneca PLC (AZN.LN) said Friday it has sold its rights outside the U.S. for nasal spray Rhinocourt Aqua to Johnson & Johnson (JNJ) affiliate Cilag GmbH International. (In "AstraZeneca Signs $330 Million Deal with Johnson & Johnson Affiliate," at 0630 GMT, the name of the nasal spray was misspelled in the first paragraph.)
(END) Dow Jones Newswires
October 07, 2016 03:36 ET (07:36 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
